116293-90-4

Usage

Uses

Used in Pharmaceutical Industry:
6-Fluoroquinoline-3-carboxylic acid is used as a key intermediate in the synthesis of various pharmaceuticals for its potential antitumor, antimicrobial, and antiviral properties. Its unique structure allows for the development of drugs with specific therapeutic targets and improved efficacy.
Used in Agrochemical Industry:
In the agrochemical sector, 6-fluoroquinoline-3-carboxylic acid serves as a crucial component in the creation of pesticides and other crop protection agents, leveraging its ability to form a broad spectrum of bioactive compounds that can combat a variety of pests and diseases.
Used in Research Applications:
6-Fluoroquinoline-3-carboxylic acid is employed as a fluorescent probe for the detection and study of reactive oxygen species in biological systems. Its fluorescent properties enable researchers to monitor oxidative processes and assess the impact of reactive oxygen species on cellular functions and overall health.
Overall, 6-fluoroquinoline-3-carboxylic acid is a valuable compound with applications spanning across multiple industries, including pharmaceuticals, agrochemicals, and research, due to its diverse biological activities and potential for further chemical modification.

InChI:InChI=1/C10H6FNO2/c11-8-1-2-9-6(4-8)3-7(5-12-9)10(13)14/h1-5H,(H,13,14)

Upstream product

• 71083-14-2 6-fluoroquinoline-3-carboxylic acid ethyl ester 
• 395-81-3 5-fluoro-2-nitrobenzaldehyde 

Relevant academic research and scientific papers

P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS

The present disclosure provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R7 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient. In another embodiment, these compounds are useful for treating respiratory dysfunction in patients by administering one or more of the compounds to a patient.

Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase

Nicotinamide N-methyltransferase (NNMT) is a fundamental cytosolic biotransforming enzyme that catalyzes the N-methylation of endogenous and exogenous xenobiotics. We have identified small molecule inhibitors of NNMT with >1000-fold range of activity and developed comprehensive structure-Activity relationships (SARs) for NNMT inhibitors. Screening of N-methylated quinolinium, isoquinolinium, pyrididium, and benzimidazolium/benzothiazolium analogues resulted in the identification of quinoliniums as a promising scaffold with very low micromolar (IC50 à 1 μM) NNMT inhibition. Computer-based docking of inhibitors to the NNMT substrate (nicotinamide)-binding site produced a robust correlation between ligand-enzyme interaction docking scores and experimentally calculated IC50 values. Predicted binding orientation of the quinolinium analogues revealed selective binding to the NNMT substrate-binding site residues and essential chemical features driving protein-ligand intermolecular interactions and NNMT inhibition. The development of this new series of small molecule NNMT inhibitors direct the future design of lead drug-like inhibitors to treat several metabolic and chronic disease conditions characterized by abnormal NNMT activity.

TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS

There is provided compounds of formula (I) wherein W is an optionally substituted aryl or heteroaryl group, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipoxygenase (e.g. 15- lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.

QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR

This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to quinoline-derived amides that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.